The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
|Videos|December 31, 2019
Experts Provide Insight on the Biggest Advances in Oncology in 2019
Author(s)OncLive Staff
OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.
Advertisement
OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.
Advertisement
Related to this article
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.
The claudin 6–targeted antibody-drug conjugate ixotatug vedotin showed antitumor activity in recurrent germ cell tumors, including after transplant.
The sacituzumab govitecan, enfortumab vedotin, and zimberelimab triplet produced early, durable responses in untreated metastatic urothelial cancer.
Surufatinib plus serplulimab and cisplatin/etoposide produced a 69.8% ORR in advanced extrapulmonary neuroendocrine carcinoma.
Efficacy outcomes in KEYNOTE-905 were consistent with a contribution of both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC.
Advertisement
Advertisement
Trending on OncLive
1
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
2
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Basser Center for BRCA Awards 2026 Global Prize to Judy Garber
5